Motilium (Domperidone 10mg)
Clinical guidance, bioequivalence criteria, and verified partner dispensing standards for Motilium (Domperidone 10mg). Reviewed by board-certified internal medicine and clinical pharmacotherapy specialists.
1. Clinical Dosing & Titration Protocols
Daily / Baseline Regimen
Gastric Motility & Reflux: 10 mg taken three times daily (TID), 15 to 30 minutes before meals. Maximum daily dose: 30 mg/day.
On-Demand / Titration Regimen
Take 15–30 minutes before meals for optimal prokinetic effect.
Contraindicated in severe hepatic impairment and patients with baseline cardiac QT prolongation.
2. Patient Administration & Safe Usage Guidelines
Take 15 to 30 minutes before meals. Do not exceed 30mg per day.
Clinical Practice & Formulary Guidelines for Motilium (Domperidone 10mg)
Westover Hills Clinic provides evidence-based pharmacological reviews, bioequivalence assessments, and clinical monitoring recommendations for chronic disease management.
3. Frequently Asked Patient Questions
Why does Domperidone not cause extrapyramidal tremors like Metoclopramide (Reglan)?
Domperidone does not readily cross the blood-brain barrier; its dopamine antagonism is strictly confined to peripheral GI receptors and the area postrema, avoiding CNS neurological tremors.
How does Domperidone improve GLP-1 induced delayed gastric fullness?
It enhances antral-duodenal contractions and coordinates pyloric relaxation, accelerating gastric transit and relieving postprandial heaviness.
4. Pharmacological Mechanism & Receptor Profile
Peripheral D2 dopamine receptor antagonist that accelerates gastric emptying, enhances duodenal motility, and treats gastroparesis and reflux without crossing the blood-brain barrier.
Rheumatology & Internal Therapeutics • Motilium (Domperidone 10mg)
5. Chemical & Human Pharmacokinetic Matrix (Tmax, Half-Life, CYP450)
| Pharmacokinetic Parameter | Clinical Metric | Therapeutic Significance |
|---|---|---|
| Peak Plasma Time (Tmax) | 0.5 to 1.0 hour | Determines latency from ingestion to peak pharmacological onset. |
| Elimination Half-Life (T½) | 7.0 to 9.0 hours | Governs duration of action and steady-state dosing intervals. |
| Peak Concentration (Cmax) | 20 ng/mL (10mg) | Maximum observed systemic concentration in human plasma. |
| Bioavailability & Food Interaction | 15% (high first-pass hepatic extraction) | Defines oral bioavailability and dietary lipid dependency. |
| Plasma Protein Binding | 91% to 93% | Governs free circulating drug fraction available for receptor binding. |
| Volume of Distribution (Vd) | 5.7 L/kg | Reflects tissue and lipid compartment penetration. |
| Hepatic Metabolism | Extensively metabolized by hepatic CYP3A4 via hydroxylation and N-dealkylation | Primary enzymatic clearance and CYP pathways. |
| Elimination / Excretion | 66% feces, 31% urine | Renal vs biliary/fecal excretion balance. |
6. Drug-Drug Interaction Matrix
| Interacting Agent / Class | Severity Tier | Clinical Mechanism & Management Strategy |
|---|---|---|
| Potent CYP3A4 Inhibitors / QT Prolonging Agents (Ketoconazole, Erythromycin) | Contraindicated | Elevates domperidone plasma levels and increases risk of cardiac ventricular arrhythmias. |
7. Adverse Reaction Profile & Clinical Incidence Rates
| Adverse Reaction | Incidence Rate | Physiological Mechanism & Mitigation Strategy |
|---|---|---|
| Dry Mouth | 3% | Mild anticholinergic sensation. |
| Headache | 2% | Transient. |
| Hyperprolactinemia / Galactorrhea | 1.5% | D2 antagonism in pituitary outside the blood-brain barrier. |
Peer-Reviewed Scientific Citations & FDA References
- Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429-440.